Skip to main content

Summarization of doxycycline for treatment of chlamydia

Changing treatment recommendations for Chlamydia trachomatis from single-dose azithromycin to a 7-day course of doxycycline has raised adherence concerns among adolescent and young adult providers. Although azithromycin remains an option for patients who are pregnant or who have significant adherence or prescription access barriers, doxycycline remains the preferred first-line treatment because it is more effective.

Two systematic reviews and meta-analyses analyzed randomized controlled trials comparing azithromycin and doxycycline for the treatment of urogenital Chlamydia trachomatis infection and found higher rates of microbiologic treatment failure among men treated with azithromycin.1,2 Additional observational studies and randomized controlled trials have shown that doxycycline is more effective than azithromycin for rectal C trachomatis infection, with reported microbiologic cure rates approaching 100% among men treated with doxycycline.3

Available evidence supports doxycycline as an effective treatment for urogenital, rectal, and oropharyngeal Chlamydia trachomatis infections. Although azithromycin remains highly effective for urogenital infection in women, its effectiveness for concomitant rectal infection remains a concern because rectal infection is common and cannot be reliably predicted by reported sexual activity.3 Inadequately treated rectal infection may increase the risk of transmission and recurrent urogenital infection through autoinoculation from the anorectal site.4

Workowski et al.3 recommend considering azithromycin 1 g as an alternative treatment option when adherence to doxycycline is a substantial concern. Because azithromycin has demonstrated lower efficacy for rectal infection, posttreatment evaluation and testing should be considered.3

 

  1. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(2):193-205. doi:10.1093/cid/ciu220
  2. Páez Canro C, Alzate JP, González LM, Rubio Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019;1(1):CD010871. doi:10.1002/14651858.CD010871.pub2
  3. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines. MMWR Recomm Rep. 2021;70(4):1-187.
  4. Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in chlamydia infected individuals. Clin Infect Dis. 2015;60(10):1585-1586. doi:10.1093/cid/civ079

 

These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.